Viewing Study NCT01868451


Ignite Creation Date: 2025-12-24 @ 11:39 PM
Ignite Modification Date: 2025-12-25 @ 9:30 PM
Study NCT ID: NCT01868451
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-07-09
First Post: 2013-05-30
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Sponsor: Memorial Sloan Kettering Cancer Center
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module